drugset / Trial / NCT00117611

Xolair in Patients With Chronic Sinusitis

NCT00117611

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.

Timeline

Start
2005-07
Primary completion
2007-05
Completion
2009-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Omalizumab Monoclonal antibody Subcutaneous